DK2099489T3 - Sammensætninger og fremgangsmåder til behandling af en neoplasme - Google Patents

Sammensætninger og fremgangsmåder til behandling af en neoplasme

Info

Publication number
DK2099489T3
DK2099489T3 DK07761925.2T DK07761925T DK2099489T3 DK 2099489 T3 DK2099489 T3 DK 2099489T3 DK 07761925 T DK07761925 T DK 07761925T DK 2099489 T3 DK2099489 T3 DK 2099489T3
Authority
DK
Denmark
Prior art keywords
neoplasm
procedures
compositions
treating
Prior art date
Application number
DK07761925.2T
Other languages
Danish (da)
English (en)
Inventor
Gregory D Plowman
Robert D Mass
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK2099489T3 publication Critical patent/DK2099489T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07761925.2T 2006-12-11 2007-05-04 Sammensætninger og fremgangsmåder til behandling af en neoplasme DK2099489T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (1)

Publication Number Publication Date
DK2099489T3 true DK2099489T3 (da) 2014-08-18

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07761925.2T DK2099489T3 (da) 2006-12-11 2007-05-04 Sammensætninger og fremgangsmåder til behandling af en neoplasme

Country Status (17)

Country Link
US (1) US20100086544A1 (show.php)
EP (1) EP2099489B1 (show.php)
JP (1) JP2010512407A (show.php)
KR (1) KR101320198B1 (show.php)
CN (1) CN101547705B (show.php)
AU (1) AU2007333565A1 (show.php)
BR (1) BRPI0717688A2 (show.php)
CA (1) CA2670707A1 (show.php)
DK (1) DK2099489T3 (show.php)
IL (1) IL198852A (show.php)
MX (1) MX2009006202A (show.php)
NZ (1) NZ577058A (show.php)
RU (1) RU2482877C2 (show.php)
SG (1) SG177891A1 (show.php)
SI (1) SI2099489T1 (show.php)
WO (1) WO2008073509A2 (show.php)
ZA (1) ZA200903489B (show.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557953T3 (es) 2006-09-29 2016-01-29 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar cáncer
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
MY188192A (en) 2011-09-23 2021-11-24 Oncomed Pharm Inc Vegf/dll4 binding agents and uses thereof
ES2689665T3 (es) * 2012-03-14 2018-11-15 Indiana University Research And Technology Corporation Compuestos y métodos para tratar la leucemia
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
PT3330259T (pt) 2015-07-27 2020-09-03 Chong Kun Dang Pharmaceutical Corp Composto derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6, e composição farmacêutica que contêm o mesmo
HUE061174T2 (hu) 2015-07-27 2023-05-28 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazol-szulfonamid-származék vegyületek mint hiszton-deacetiláz-6 inhibitorok, és az ilyen vegyületeket tartalmazó gyógyszerkészímény
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
EP3331864B1 (en) 2015-08-04 2021-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
RU2695133C1 (ru) 2015-10-12 2019-07-22 Чонг Кун Данг Фармасьютикал Корп. Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102491040B1 (ko) 2019-05-31 2023-01-25 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 호모프탈이미드 유도체 화합물 및 이를 포함하는 약제학적 조성물
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
NZ510845A (en) * 1998-09-25 2003-10-31 Boehringer Ingelheim Pharma Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-vegf抗體

Also Published As

Publication number Publication date
NZ577058A (en) 2012-04-27
WO2008073509A3 (en) 2009-01-08
AU2007333565A1 (en) 2008-06-19
KR101320198B1 (ko) 2013-10-30
ZA200903489B (en) 2010-08-25
RU2482877C2 (ru) 2013-05-27
RU2009126588A (ru) 2011-01-20
EP2099489B1 (en) 2014-05-21
CN101547705A (zh) 2009-09-30
CA2670707A1 (en) 2008-06-19
US20100086544A1 (en) 2010-04-08
MX2009006202A (es) 2009-06-22
IL198852A (en) 2013-06-27
JP2010512407A (ja) 2010-04-22
IL198852A0 (en) 2011-08-01
SG177891A1 (en) 2012-02-28
CN101547705B (zh) 2013-06-12
HK1131064A1 (en) 2010-01-15
KR20090087908A (ko) 2009-08-18
SI2099489T1 (sl) 2014-09-30
WO2008073509A2 (en) 2008-06-19
BRPI0717688A2 (pt) 2013-01-22
EP2099489A2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
DK2099489T3 (da) Sammensætninger og fremgangsmåder til behandling af en neoplasme
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2032156T3 (da) Sammensætninger og fremgangsmåder til levering af oxygen
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2061561T3 (da) Sammensætninger til behandling af cancer
DK1969099T3 (da) Fremgangsmåde og indretning til behandling af biomasse
DK2334932T4 (da) Anordning og fremgangsmåde til fremstilling af en anordning
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2495327T3 (da) Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
DK1969007T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK3006459T3 (da) Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2133134T3 (da) Anordning og fremgangsmåde til behandling af udstødningsgas
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2222999T3 (da) Fremgangsmåde til formning af en klemring og en klemring
DK2187880T3 (da) Sammensætninger og fremgangsmåder til behandling af makuladegeneration